Nivolumab in metastatic melanoma: good efficacy and tolerability in elderly patients.

Conclusions: Nivolumab is an immunotherapy treatment that has proved to be an effective and well-tolerated therapeutic option in elderly patients with metastatic melanoma. PMID: 32489255 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/32489255?dopt=Abstract

Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research